Drug Profile
Research programme: multiple sclerosis therapeutics - Hard to Treat Diseases
Alternative Names: GIFT-15; Ribavirin/tiazofurine; Tiazofurine/ribavirinLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hard To Treat Diseases
- Developer Hard To Treat Diseases; Slavica Biochem
- Class Amides; Glycoproteins; Haematopoietic cell growth factors; Interleukins; Purine nucleosides; Ribonucleosides; Small molecules; Thiazoles
- Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Canada (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Serbia
- 14 Aug 2009 Preclinical trials in Multiple sclerosis in Canada (IV)